NVAX NOVAVAX INC
Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR NOVAVAX INC (NVAX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Management Discussion & Analysis
- • Q3 revenue $70.4M, down $14.1M YoY from $84.5M; product sales $13.4M vs $41.5M, licensing up $14.0M to $57.0M
- • Q3 net loss $202.4M vs $121.3M YoY; operating expenses rose 13.7% to $248.5M; impairment loss $97M and $28.7M debt extinguishment loss impacted results
Risk Factors
- • New FDA framework requiring placebo-controlled trials for COVID-19 vaccines in healthy under 65 population, increasing expenses and approval delays
- • PMC post-approval clinical trial amendments requested by FDA, potential cost increases subject to Sanofi negotiations and reimbursement terms
Get deeper insights on NOVAVAX INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.